WO2026119121 - FUSED RING COMPOUND AND PHARMACEUTICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/119121
Publication Date
11.06.2026
International Application No.
PCT/CN2025/139307
International Filing Date
02.12.2025
Title **
[English]
FUSED RING COMPOUND AND PHARMACEUTICAL USE THEREOF
[French]
COMPOSÉ À CYCLES FUSIONNÉS ET UTILISATION PHARMACEUTIQUE DE CELUI-CI
[Chinese]
稠环化合物及其医药用途
Applicants **
SHANDONG SIMCERE ZAIMING BIOPHARMACEUTICAL CO., LTD.
Inventors
JIN, Jinghai
ZHANG, Fan
ZHU, Wei
JIANG, Lei
LI, Zhengtao
Priority Data
202411751770.X
02.12.2024
CN
202510197743.0
21.02.2025
CN
202510403557.8
01.04.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2461 | |
| EPO | Filing, Examination, Granting | 18057 | |
| Japan | Filing, Examination, Granting | 2480 | |
| South Korea | Filing, Examination, Granting | 2833 | |
| USA | Filing, Examination, Granting | 5740 |
Total:
31,571
Contact Us
Abstract[English]
The present disclosure relates to a CDK4 inhibitor compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for preventing or treating CDK4-mediated diseases.[French]
La présente divulgation concerne un composé inhibiteur de CDK4 représenté par la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique le contenant, ainsi que son utilisation dans la préparation d'un médicament destiné à prévenir ou à traiter des maladies médiées par CDK4.[Chinese]
本公开涉及式(I)所示CDK4抑制剂化合物或其药学上可接受的盐、含有它们的药物组合物、以及其在制备预防或治疗CDK4介导的疾病中的用途。